- Home
- GLUE vs ZD Comparison
GLUE vs ZD Comparison
Compare GLUE & ZD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GLUE | ZD |
|---|---|---|
| Founded | 2019 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Advertising |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.7B |
| IPO Year | 2021 | 1999 |
Fundamental Metrics
Financial Performance| Metric | GLUE | ZD |
|---|---|---|
| Price | $22.15 | $52.54 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 7 |
| Target Price | $32.00 | ★ $39.71 |
| AVG Volume (30 Days) | ★ 1.2M | 605.3K |
| Earning Date | 05-08-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.59 |
| Revenue | $123,672,000.00 | ★ $1,364,028,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.45 | $2.16 |
| P/E Ratio | ★ $72.42 | $88.75 |
| Revenue Growth | ★ 63.54 | N/A |
| 52 Week Low | $4.12 | $22.45 |
| 52 Week High | $25.77 | $54.97 |
Technical Indicators
Market Signals| Indicator | GLUE | ZD |
|---|---|---|
| Relative Strength Index (RSI) | 47.73 | 58.68 |
| Support Level | $17.35 | $50.44 |
| Resistance Level | $25.38 | $54.86 |
| Average True Range (ATR) | 1.51 | 1.64 |
| MACD | -0.32 | -0.33 |
| Stochastic Oscillator | 27.51 | 51.43 |
Price Performance
Historical ComparisonAbout GLUE Monte Rosa Therapeutics Inc.
Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. The company has three programs in clinical development: MRT-6160, a VAV1-directed MGD for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for inflammatory diseases driven by IL-6, and the NLRP3 inflammasome; and MRT-2359, a GSPT1-directed MGD for metastatic castration resistant prostate cancer (mCRPC).
About ZD Ziff Davis Inc.
Ziff Davis Inc is a digital media and internet company operating a portfolio of brands across technology, shopping, gaming and entertainment, health and wellness, connectivity, and cybersecurity. The company has five reportable segments. The Technology & Shopping segment generates revenue from advertising and commerce content. The Gaming & Entertainment segment provides content, subscriptions, and digital storefront services. The Health & Wellness segment offers digital tools and content for health management. The Connectivity segment provides data and analytics solutions for network performance. The Cybersecurity & Martech segment delivers cloud-based software for security and marketing. It generates the majority of its revenue from the Health & Wellness segment.